Trial Profile
Phase I Study of Radiation Therapy With Concurrent Sorafenib for Hepatocellular Carcinoma Not Responding to Transarterial Chemoembolization
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- 04 Sep 2013 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov record.
- 31 Jul 2012 Actual initiation date (1 Jun 2012) added as reported by ClinicalTrials.gov record.
- 31 Jul 2012 Planned number of patients (30) added as reported by ClinicalTrials.gov record.